Kura Oncology (KURA) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is KURA's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

Kura Oncology, Inc. ( KURA ) UBS Global Biopharma Conference 2026 November 17, 2026 8:20 AM EST Company Participants Jennifer Fulk - Chief Financial Officer Brian Powl - Chief Commercial Officer Mollie Leoni - Chief Medi…

Kura Oncology is a BUY: KOMZIFTI uptake and a roughly $202 million enterprise value support a measured event-driven position. KOMZIFTI prescriptions outpaced new starts, suggesting growing refills; patient-level persiste…

SAN DIEGO, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that management will present at the…

Kura Oncology, Inc. ( KURA ) Q3 2026 Earnings Call November 10, 2026 4:30 PM EST Company Participants Greg Mann - Senior Vice President of Investor Relations & Corporate Affairs Troy Wilson - Chairman, CEO & President Br…

Kura Oncology NASDAQ: KURA reported third-quarter 2026 net product revenue of $13.9 million for leukemia treatment KOMZIFTI, up 53% from the prior quarter, as the company expanded prescribing accounts and prepared clinic…

Kura Oncology (KURA) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to a loss of $0.85 per share a year ago.…

– KOMZIFTI ® (ziftomenib) net product revenue grew 53% sequentially to $13.9 million; new patient starts increased 30% and total prescriptions grew 65% – – KOMZIFTI maintained majority share of new patient starts of the …

Kura Oncology (KURA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a…

SAN DIEGO, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that on November 2,…

– Two oral presentations to feature first ziftomenib combination data with quizartinib in newly diagnosed and gilteritinib in relapsed/refractory NPM1/FLT3 co-mutated AML –…

SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced it will report its third quarter 20…

Kura Oncology (KURA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

Kura Oncology NASDAQ: KURA and its newly formed affiliate Caspian Therapeutics outlined plans to develop KO-7246, an oral menin inhibitor, for diabetes, citing preclinical data that the companies said showed beta-cell ex…

Kura Oncology, Inc. (KURA) Discusses KO-7246 Data and Development Strategy for Menin Inhibitors in Diabetes Transcript…

– EASD findings support clinical evaluation of a next-generation oral menin inhibitor designed to restore insulin-producing capacity – – IND-enabling development underway to support Phase 1 clinical proof-of-concept stud…

– Webcast scheduled for October 13, 2026, at 4:30 p.m. ET / 1:30 p.m. PT – – Webcast scheduled for October 13, 2026, at 4:30 p.m. ET / 1:30 p.m. PT –…

SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that on October 1, …

Squarepoint Ops LLC lessened its stake in shares of Kura Oncology, Inc. (NASDAQ: KURA) by 88.5% in a recent quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1…

Kura Oncology, Inc. (KURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

– $50 million financing led by BVF Partners with participation from the T1D Fund, Invus, Montanova, Eli Lilly and Company, Kura Oncology, members of the Kura leadership team, and multiple, successful biotech entrepreneur…

– Seasoned public company CFO with deep biopharmaceutical finance experience across commercial operations, R&D portfolio management, investor relations, and capital allocation – SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE…

SAN DIEGO, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that on September …

Kura's rising Komzifti sales, promising AML data and pipeline catalysts boost investor confidence and fuel KURA's gains.…

SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that management will present at th…
Kept in their own lane. A press release is the company talking, not reporting.
No upcoming events in the feeds.

